scholarly journals STUDY OF CLINICAL FEATURES AND EPIDEMIOLOGY OF COMPLICATED VIVAX MALARIA

2019 ◽  
Vol 7 (9) ◽  
pp. 47-51
Author(s):  
Arvind Mathur ◽  
Mohit Kackar ◽  
Indu Thanvi ◽  
Harish Agarwal
Keyword(s):  
Distress Syndrome ◽  
Falciparum Infection ◽  
World Health ◽  
Severe Anemia ◽  
Spontaneous Bleeding ◽  
Complicated Malaria ◽  
The World ◽  
Action Programme ◽  
Splenic Uptake ◽  
Health Organization

Severe and complicated malaria is defined by the World Health Organization Malaria Action Programme in June 19851 as the presence of one or more of the following conditions in a slide confirmed diagnosed case of malaria cerebral malaria, severe anemia, renal failure, pulmonary edema or adult respiratory distress syndrome, hypoglycemia, circulatory collapse or shock, spontaneous bleeding, repeated generalized convulsions, acidemia or acidosis, macroscopic hemoglobinuria, impairment of consciousness less marked than unarousable coma,, hyperparasitemia, jaundice, hyperpyrexia, and the presence of complicating or associated infections. However, severe anemia and thrombocytopenia that causes bleeding diatesis is produced by hemolysis, reduced cell deformity of parasitized and non-parasitized erythrocytes, increased splenic clearance, reduction of platelet survival, decreased platelet production, and increased splenic uptake of platelets. Though these changes can be produced by P. vivax and P. falciparum infection yet the complicated malaria has commonly been associated with P. falciparum infections.

OBESITY IN SARS-COV-2 INFECTION: LITERATURE REVIEW

2021 ◽  
pp. 19-23
Author(s):  
Donizete Tavares Da Silva ◽  
Priscila De Sousa Barros Lima ◽  
Renato Sampaio Mello Neto ◽  
Gustavo Magalhães Valente ◽  
Débora Dias Cabral ◽  
...  
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Gastrointestinal Tract ◽  
Severe Acute Respiratory Syndrome ◽  
Distress Syndrome ◽  
Circulatory System ◽  
World Health ◽  
Global Public Health ◽  
The World ◽  
Health Organization

In March 2020, the World Health Organization (1) declared COVID-19 as a pandemic and a threat to global public health (2). The virus mainly affects the lungs and can cause acute respiratory distress syndrome (ARDS). In addition, coronavirus 2 severe acute respiratory syndrome (SARSCOV2) also has devastating effects on other important organs, including the circulatory system, brain, gastrointestinal tract, kidneys and liver

scholarly journals How to Control Covid-19 with a Nanobiotherapy?

2020 ◽  
Keyword(s):  
Intensive Care Unit ◽  
Immune Response ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
World Health ◽  
Shortness Of Breath ◽  
The World ◽  
Health Organization ◽  
Muscle Ache

The outbreak of emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) in China has been brought to global attention and declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In a recent study of Nanshan Chen et al., on patients of Wuhan Jinyintan Hospital, Wuhan, China, from the 99 patients with SARSCoV-2 infection, 51% had chronic diseases and they had symptoms of fever (83%), cough (82%) shortness of breath (31%), muscle ache (11%), fatigue (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), diarrhea (2%), and nausea and vomiting (1%) [1, 2]. The majority of patients can recover, however, about 25% of patients will progress into severe complications including acute respiratory distress syndrome (ARDS), which may worsen rapidly into respiratory failure, need an intensive care unit (ICU) and even cause multiple organ failure [3]. Depending on the pathophysiological mechanisms supposed to be involved in the development of the various clinical forms of the disease, various types of treatment have been tested with varying degrees of success. We have developed a nanotherapy to block the entry of the virus into the host cell, to reduce its potential for replication and to regulate the immune response against the microbial aggressor [4].

scholarly journals COVID-19- or Tramadol-induced Seizure: A Differential Diagnosis in Young People

2020 ◽  
Vol 10 (4) ◽  
pp. 32009.1-32009.2
Author(s):  
Solmaz Nekoueifard ◽  
◽  
Mohammad Majidi ◽  
Keyword(s):  
Myocardial Infarction ◽  
Acute Kidney Injury ◽  
Differential Diagnosis ◽  
Acute Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Kidney Injury ◽  
World Health ◽  
The World ◽  
Life Threatening ◽  
Health Organization

Coronavirus disease 2019 (COVID-19) was first declared in December 2019 from Wuhan, China [1, 2]. It then has been reported a pandemic in March 2020 by the World Health Organization [3]. Clinical features of COVID-19 are different from asymptomatic to mild to moderate symptoms, such as fever, headache, myalgia, sore throat, anosmia, cough, fatigue headache, hemoptysis, and dyspnea to the life-threatening complications, including shock, pneumonia, acute respiratory distress syndrome, myocarditis, myocardial infarction, acute kidney injury, multi-organ failure, and even death [1, 2].

scholarly journals Mental health e-supervision for primary care doctors in Sudan using the WHO mhGAP Intervention Guide

2015 ◽  
Vol 12 (S1) ◽  
pp. S-16-S-19 ◽  
Author(s):  
Anne Aboaja ◽  
Puja Myles ◽  
Peter Hughes
Keyword(s):  
Mental Health ◽  
Primary Care ◽  
World Health ◽  
Middle Income ◽  
Middle Income Countries ◽  
The World ◽  
Health Gap ◽  
Action Programme ◽  
Primary Care Doctors ◽  
Health Organization

This paper describes the evaluation of a pilot e-supervision programme, with a focus on feasibility. The findings suggest that e-supervision in mental health using the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP) Intervention Guide and case-based discussions is valued by participants and can improve the knowledge, confidence and beliefs of primary care doctors in low- and middle-income countries.

scholarly journals Does the Use of Dihydroartemisinin-Piperaquine in Treating Patients with Uncomplicated falciparum Malaria Reduce the Risk for Recurrent New falciparum Infection More Than Artemether-Lumefantrine?

2014 ◽  
Vol 2014 ◽  
pp. 1-20 ◽  
Author(s):  
Wisdom Akpaloo ◽  
Edward Purssell
Keyword(s):  
Disease Burden ◽  
Falciparum Infection ◽  
World Health ◽  
Combination Therapies ◽  
Randomized Controlled ◽  
Cochrane Database ◽  
Significant Difference ◽  
The World ◽  
Health Organization ◽  
Global Disease Burden

Malaria contributes significantly to the global disease burden. The World Health Organization recommended the use of artemisinin-based combination therapies (ACTs) for treatment of uncomplicated falciparum malaria a decade ago in response to problems of drug resistance. This review compared two of the ACTs—Dihydroartemisinin-Piperaquine (DP) and Artemether-Lumefantrine (AL) to provide evidence which one has the ability to offer superior posttreatment prophylaxis at 28 and 42 days posttreatment. Four databases (MEDLINE, EMBASE, Cochrane Database and Global Health) were searched on June 2, 2013 and a total of seven randomized controlled trials conducted in sub-Sahara Africa were included. Results involving 2, 340 participants indicates that reduction in risk for recurrent new falciparum infections (RNIs) was 79% at day 28 in favour of DP [RR, 0.21; 95% CI: 0.14 to 0.32, P<0.001], and at day 42 was 44% favouring DP [RR, 0.56; 95% CI: 0.34 to 0.90; P=0.02]. No significant difference was seen in treatment failure rates between the two drugs at days 28 and 42. It is concluded that use of DP offers superior posttreatment prophylaxis compared to AL in the study areas. Hence DP can help reduce malaria cases in such areas more than AL.

scholarly journals The WHO mhGAP Intervention Guide for people with intellectual disability: the Sri Lankan experience

2015 ◽  
Vol 12 (S1) ◽  
pp. S-19-S-23
Author(s):  
Rohit Gumber ◽  
Shweta Gangavati ◽  
Sabyasachi Bhaumik ◽  
Sherva Cooray ◽  
Kiran Purandare ◽  
...  
Keyword(s):  
Mental Health ◽  
Intellectual Disability ◽  
Pilot Project ◽  
World Health ◽  
Sri Lankan ◽  
Treatment Gap ◽  
The World ◽  
Health Gap ◽  
Action Programme ◽  
Health Organization

In recognition of the treatment gap in mental health, the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP) was launched in 2008 and has proved successful. The paper describes the launch of the first mhGAP intellectual disabilities pilot project in Sri Lanka. It reports on the development of the materials and the key lessons learnt.

scholarly journals COVID-19 in ophthalmic practice

2020 ◽  
Author(s):  
KhP Takhchidi ◽  
NKh Takhchidi ◽  
MKh Movsesian
Keyword(s):  
Public Health ◽  
Diabetes Mellitus ◽  
Distress Syndrome ◽  
Meta Analysis ◽  
World Health ◽  
The Past ◽  
Ocular Manifestations ◽  
The World ◽  
Coronavirus Infection ◽  
Health Organization

The end of 2019 in China was marked by the breakout of the new Coronavirus Disease (COVID-19) caused by the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). Gradually, the infection spread around the world and in March 2020, the World Health Organization (WHO) declared Covid-19 a pandemic. The new coronavirus disease 2019 is highly contagious, causing respiratory distress syndrome and poses a huge threat to public health, especially in patients. with serious concomitant diseases such as diabetes mellitus, bronchial asthma, hypertension, etc. Many scientists have put forward the idea that COVID-19 can be transmitted through the eyes through contact and everyday life. Over the past six months, works on the ocular manifestations of coronavirus infection have begun to appear in the literature. We conducted a systematic review of scientific articles from the PubMed, e-Library, Scopus databases in order to conduct a meta-analysis of the effect of coronavirus infection on the eyes and its ophthalmological manifestations.

scholarly journals Tailoring a training based on the Mental Health Gap Action Programme (mhGAP) Intervention Guide (IG) to Tunisia: process and relevant adaptations

2018 ◽  
Vol 5 ◽  
Author(s):  
Jessica Spagnolo ◽  
François Champagne ◽  
Nicole Leduc ◽  
Wahid Melki ◽  
Imen Guesmi ◽  
...  
Keyword(s):  
Mental Health ◽  
World Health Organization ◽  
Mental Health Treatment ◽  
Training Programme ◽  
World Health ◽  
Adaptation Process ◽  
The World ◽  
Health Gap ◽  
Action Programme ◽  
Health Organization

BackgroundIn order to make mental health services more accessible, the Tunisian Ministry of Health, in collaboration with the School of Public Health at the University of Montreal, the World Health Organization office in Tunisia and the Montreal World Health Organization-Pan American Health Organization Collaborating Center for Research and Training in Mental Health, implemented a training programme based on the Mental Health Gap Action Programme (mhGAP) Intervention Guide (IG) (version 1.0), developed by the World Health Organization. This article describes the phase prior to the implementation of the training, which was offered to general practitioners working in primary care settings in the Greater Tunis area of Tunisia.MethodsThe phase prior to implementation consisted of adapting the standard mhGAP-IG (version 1.0) to the local primary healthcare context. This adaptation process, an essential step before piloting the training, involved discussions with stakeholder groups, as well as field observations.ResultsThrough the adaptation process, we were able to make changes to the standard training format and material. In addition, the process helped uncover systemic barriers to effective mental health care.ConclusionsTargeting these barriers in addition to implementing a training programme may help reduce the mental health treatment gap, and promote implementation that is successful and sustainable.

scholarly journals Multiorgan Involvement in COVID-19 and Possible Therapies

2020 ◽  
Vol 04 (01) ◽  
pp. 20-24
Author(s):  
Prachee Sathe ◽  
Vijay Sundar Singh
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
World Health Organization ◽  
Distress Syndrome ◽  
Respiratory Illness ◽  
World Health ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

AbstractIn late 2019, China reported cases of respiratory illness in humans, which involved a novel Coronavirus SARS-CoV-2 (also known as 2019-nCoV). The World Health Organization (WHO) termed the disease COVID-19 (i.e., Coronavirus disease 2019). Most of the morbidity and mortality from COVID-19 is largely due to acute viral pneumonitis that leads to acute respiratory distress syndrome (ARDS). This article will discuss the clinical features of the multiorgan involvement in COVID-19 as well as the management of patients who become critically ill due to COVID-19.

scholarly journals Prospects of plasmapheresis for patients with severe COVID-19

2020 ◽  
Author(s):  
Ilmira R. Gilmutdinova ◽  
Maksim Yu. Yakovlev ◽  
Petr S. Eremin ◽  
Anatoliy D. Fesun
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Distress Syndrome ◽  
International Committee ◽  
World Health ◽  
Cytokine Storm ◽  
Positive Experience ◽  
Cytokine Levels ◽  
The World ◽  
Health Organization

On February 11, 2020, the World Health Organization officially named the infection caused by the new coronavirus “Coronavirus disease 2019” (COVID-19). On February 11, 2020, the International Committee on Taxonomy of Viruses (ICTV) officially named the infectious matter “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). Emergence of severe complications with new coronavirus disease is due to the development of hypercytokinaemia, also known as “cytokine storm”. These complications comprise acute respiratory distress syndrome (ARDS), respiratory failure and death. Emerging data point to the logic of using extracorporeal haemocorrection to normalise cytokine levels and reduce the severity of organ disorders. The analysis of the literature indicates that to date, a certain positive experience has been accumulated in the world in the application of extracorporeal methods in clinical practice in patients with COVID-19.

Sign in / Sign up

Export Citation Format

Share Document